Literature DB >> 6883908

Effects of piretanide in normal subjects.

D C Brater, S Anderson, B Baird, S Kaojarern.   

Abstract

Piretanide is a new loop diuretic similar to furosemide in pharmacologic properties and approximately six times as potent. We gave 3-, 6-, and 12-mg oral doses to 21 normal subjects and collected serial blood and urine samples for assessment of the drug's kinetics and dynamics. There was no evidence for dose-dependent elimination with the doses we used. Peak serum concentrations and urinary excretion rates appeared between 30 and 60 min. Elimination t1/2s were 60 to 90 min. Approximately 45% of a dose was recovered unchanged in the urine. Renal clearance rate was 90 to 100 ml/min and oral clearance was 200 ml/min. Examination of the relationship between urinary excretion rate of piretanide and sodium excretion allowed determination of potency at the tubular level. The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide. Piretanide kinetics, therefore, resemble those of furosemide and bumetanide, but piretanide is five or six times as potent as furosemide and one tenth as potent as bumetanide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883908     DOI: 10.1038/clpt.1983.175

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  The influence of ascites on the pharmacokinetics of piretanide in cirrhotic patients.

Authors:  A N Shepherd; I A Bouchier
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 3.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

5.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Diuretic strategies in patients with renal failure.

Authors:  S K Swan
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

7.  Pharmacokinetics of the loop diuretic piretanide in renal failure.

Authors:  U Walter; A Röckel; W Lahn; A Heidland; W Heptner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.